Preclinical study demonstrates that furanose-based sugar amino acid linkers enable PSMA-targeted radiotracer uptake in mice, indicating a viable method for pharmacokinetic optimization.
The pronounced lipophilicity of tert ‐butyl‐substituted silicon‐fluoride‐acceptor (SiFA) scaffolds represents a major limitation in radiotracer development, often resulting in elevated nonspecific uptake and reduced tumor‐to‐background ratios. To address this challenge, we designed and synthesized a series of prostate‐specific membrane antigen (PSMA)‐targeted radioligands incorporating furanose‐ and pyranose‐based sugar amino acid (SAA) linkers to evaluate physicochemical properties while maintaining efficient 18 F‐radiolabeling capability. Six compounds ( 19 –24 ) were prepared via a convergent three‐step synthesis in 35%–75% overall yield. Furanose‐SAA derivatives ( 19–22 ) retained moderate PSMA binding affinity (IC 50 = 5–19 µM), while pyranose‐SAA analogues 23 and 24 were inactive (IC 50 > 100 µM). All compounds exhibited similar lipophilicity (log P = 3.10–3.42), indicating that the differences in biological activity are not primarily attributable to lipophilicity. Compounds 19 and 21 were radiolabeled via isotopic exchange in 25%–40% radiochemical yield with molar activity of 86 ± 3 GBq/µmol. PET imaging in LNCaP xenograft mice demonstrated that [ 18 F]21 , bearing three furanose‐SAA units, achieved SUV 60min = 0.64 ± 0.06 with ~30% blocking by DCFPyL, confirming partial PSMA‐mediated uptake. This proof‐of‐concept study establishes SAA linkers as a viable strategy for pharmacokinetic optimization of SiFA‐based radiotracers, warranting further structural refinement to enhance target affinity.
No takes yet. Share an insight, caveat, or question.
Gade et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: